Your acting like every trial has been disappointing. When I would contend that none of the trials have been disappointing. We have learned valuable information from both of the phase 2 trials for covid as we should of. We have learned a lot from every trial. We have designed our phase 3 trials for Covid to be successful based on what we have learned. As we will for Cancer and Nash when and if they also require a phase 3 and don’t get a BTD.

As much as I want a BTD I don’t believe a 100% that we will get the BTD’s we all want. But will we have valuable lessons learned for Nash and Cancer? Yes we will. Will they be enough for a BTD… yes they will in our view but sample size or patient size is always our downfall. That’s what holds us back in my opinion. The FDA wants more people in trials than we have had. This won’t be a problem after our first approval because money talks and our trials will then be affordable for us with revenue supplying the much needed income to further our trials.

This is the normal expectations that we should of expected. Knowing that a phase 2 is rarely approved we know now we are sitting in the cat birds seat as the phase 3 trials start. Waiting for what we have learned to get us the results we now expect. So should we expect a stock price jump on starting of the covid trials in Brazil? Maybe, you or I will not expect it but many will see it as a big deal and who knows how much of a jump it might take. It really starts a clock ticking of approximately 3 months or less to interim results. This is something that will be a big deal for me and hopefully all of us get on board with these catalysts. Thinking positive with high expectations isn't a bad thing knowing what we know and following our past trial successes.

As I always say… we are looking at good times in the near future. I keep saying it and now I believe it more than ever! Good times are so close…